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Edited by Laszlo NagyAbstract Adiponectin, one of the adipokines secreted by adipo-
cytes, possesses insulin sensitizing and anti-atherosclerotic prop-
erties. Tumor necrosis factor-alpha (TNF-a) is known to
suppress the expression and secretion of adiponectin in adipo-
cytes; however, the underlying mechanism remains poorly under-
stood. Here, we demonstrate that GO6976 (a selective inhibitor
of conventional protein kinase C (PKC)) prevents TNF-a-in-
duced suppression of adiponectin secretion and expression in
fully diﬀerentiated 3T3-L1 adipocytes, accompanied by attenua-
tion of c-Jun N-terminal kinase (JNK) activation. Additionally,
the transcriptional activity of peroxisome proliferator-activated
receptor-gamma (PPARg) (a strong inducer of adiponectin) on
the adiponectin promoter was inhibited in a PKC isoform-spe-
ciﬁc manner. These results raise the possibility that PKC is in-
volved in TNF-a-induced suppression of adiponectin in 3T3-L1
adipocytes.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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factor-alpha; Protein kinase C1. Introduction
Adiponectin, also known as Acrp30, AdipoQ, apM1, and
GBP28, is a 30-kD plasma protein. Initially, adiponectin was
known to be exclusively expressed and secreted in adipose tis-
sues; however, it is recently detected in non-adipose tissues as
well [1,2]. Plasma concentration and mRNA expression of
adiponectin are decreased in human patients and animal mod-
els that exhibit insulin resistance, which strongly correlates
with conditions of metabolic syndromes such as type-2 diabe-
tes and obesity [3]. In contrast, tumor necrosis factor-alpha
(TNF-a), another adipokine released by adipose tissues, are
markedly elevated in obese or diabetic animals and humans
[4], and directly contribute to the reduction of adiponectin in
adipocytes [5]. In a mouse model, adiponectin deﬁciency wasAbbreviations: TNF-a, tumor necrosis factor-alpha; PKC, protein
kinase C; PPARc, peroxisome proliferator-activated receptor-gamma;
JNK, c-Jun N-terminal kinase; MAPK, mitogen activated protein
kinase; ERK, extracellular regulated kinase
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doi:10.1016/j.febslet.2008.09.012associated with severe diet-induced insulin resistance and
elevated TNF-a levels [6]. Conversely, chronic injection of
adiponectin into insulin-resistant animals enhanced insulin
sensitivity by activating glucose uptake and fatty acid oxida-
tion, implying that adiponectin has an insulin sensitizing eﬀect
[7]. The reciprocal relationship between decreased adiponectin
and increased TNF-a levels in plasma was also reported in
chronic alcohol-fed animals, in which adiponectin treatment
attenuates alcohol-induced liver disease [8,9]. Thus, adiponec-
tin and TNF-a are reciprocally expressed in adipocytes and
have opposing eﬀects on the regulation of insulin resistance.
Although many investigators have tried to elucidate the
molecular basis of TNF-a-induced downregulation of adipo-
nectin expression in adipocytes, the underlying signaling mech-
anisms are not fully understood. TNF-a suppresses the
expression and transcriptional activity of adipogenic transcrip-
tion factors such as peroxisome proliferator-activated recep-
tor-gamma (PPARc), CCAAT/enhancer binding protein (C/
EBP), and sterol regulatory element binding protein-1c
(SREBP-1c), which are strong transcriptional inducers of
adiponectin [10–12]. In addition, TNF-a activates c-Jun N-ter-
minal kinase (JNK) to suppress adiponectin secretion [13].
Protein kinase C (PKC) plays a role in several TNF-a-in-
duced biological functions. PKC mediates TNF-a-dependent
induction of plasminogen activator inhibitor-1 (PAI-1) in
3T3-L1 adipocytes [14]. PKC also suppresses obese gene
expression and leptin secretion in adipocytes [15]. Pretreatment
with PKC inhibitors such as bisindolylmaleimide I (BIM) or 1-
(5-isoquinolinesulfonyl)-2-methyl-piperazine dihydrochloride
(H-7) restores adipogenic gene expression suppressed by
TNF-a. These observations indicate that PKC may be an
important signaling mediator in TNF-a-induced biological
functions in adipocytes.
In this study, we show that GO6976, a selective PKC inhib-
itor, prevents TNF-a-induced suppression of adiponectin
secretion and expression as well as the transcriptional activity
of PPARc on adiponectin promoter. Moreover, overexpres-
sion of PKCa and PKCb inhibited PPARc-induced adiponec-
tin promoter activity. Collectively, PKC might be involved in
TNF-a-induced suppression of adiponectin expression in fully
diﬀerentiated 3T3-L1 adipocytes.2. Materials and methods
2.1. Cell culture and adipocyte diﬀerentiation
3T3-L1 preadipocytes and HEK293 cells were maintained in Dul-
beccos modiﬁed essential medium (DMEM) containing 10% heat-
inactivated fetal bovine serum (FBS) and supplemented with 100 U/blished by Elsevier B.V. All rights reserved.
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CO2 atmosphere at 37 C. To induce adipocyte diﬀerentiation, 3T3-
L1 cells were cultured as previously described with minor modiﬁcation
[16]. Brieﬂy, cells were maintained in growth medium until 2 days after
conﬂuence, when diﬀerentiation was induced by incubation in growth
medium containing 0.1 lM dexamethasone, 0.5 mM isobutylmethyl-
xanthine (IBMX), and 10 lg/ml insulin for 3 days. After further incu-
bation for 4–5 days in growth medium containing only insulin, more
than 90% of cells diﬀerentiated into adipocytes exhibiting triglyceride
accumulation.
2.2. Materials
DMEM, FBS, penicillin, and streptomycin were purchased from
GIBCO BRL (Rockville, MD). Dexamethasone, IBMX, and insulin
were from Sigma–Aldrich (St. Louis, MO). All chemical inhibitors
including PKC inhibitor GO6976 were obtained from Calbiochem
(San Diego, CA). Anti-adiponectin and anti-phospho-JNK antibodies
were purchased from abCam (Cambridge, UK). Anti-actin, anti-
p38MAPK, anti-ATF2, anti-ERK, anti-phospho-ERK, anti-c-Jun,
and anti-phospho-c-Jun antibodies were purchased from Santa Cruz
Biotechnology (Santa Cruz, CA). Anti-phospho-p38MAPK and anti-
phospho-ATF2 antibodies were purchased from Cell Signaling Tech-
nology (Beverly, MA). Recombinant mouse TNF-a was obtained from
R&D (Minneapolis, MN).Fig. 1. PKC inhibitor GO6976 alleviates TNF-a-induced suppression of adip
adipocytes were serum starved for 6 h and then pretreated with various prot
1 lMGO6976; U, 10 lMU0126) for 1 h prior to further 24 h incubation with
by immunoblotting using 40 ll culture medium. (B) After serum starvation fo
of GO6976 (0.01–2 lM) for 1 h prior to addition of TNF-a (10 ng/ml). The ﬁ
the graph represents mean value of quantiﬁcations by densitometric analysis2.3. Transfection and luciferase assay
PPRE-luc and PPARc expression vectors were kindly provided by
Dr. JaeHun Cheong (Pusan National University, Korea). An adipo-
nectin promoter-luc vector containing the mouse adiponectin pro-
moter spanning 1500 to +50 bp was obtained from Dr. Hyun Bae
Kim (National Institute of Health, Korea). PKC expression vectors
were kindly provided by Dr. Jae-Won Soh (Inha University, Korea).
For the transactivation assay, the luciferase reporter plasmid was co-
transfected with b-galactosidase using lipofectamine (Invitrogen)
according to the manufacturers protocol. Twenty hours post transfec-
tion, cells were lysed with reporter lysis buﬀer (200 ll/well, Promega),
and luciferase activity was measured using the luciferase reporter assay
system (Promega). b-Galactosidase activity was used to normalize
transfection eﬃciency.
2.4. Reverse transcriptase-polymerase chain reaction (RT-PCR) and
semi-quantitative PCR
First strand cDNA synthesis was performed with 1 lg of total RNA
extracted using Trizol (Invitrogen) and reverse-transcriptase MMLV
(Invitrogen). The oligonucleotide primers for semi-quantitative PCR
were as follows: mouse adiponectin, 5 0-TGGATCTGACGACAC-
CAAAA-3 0 (forward) and 5 0-CGAATGGGTACATTGGGAAC-3 0
(reverse); mouse PAI-1, 5 0-ATGAGATCAGTACTGCGGATGCC-
3 0 (forward) and 5 0-AGAGACGGTGCTGCCATCAG-30 (reverse);onectin secretion in 3T3-L1 adipocytes. (A) Fully diﬀerentiated 3T3-L
ein kinase inhibitors (SP, 50 lM SP600125; SB, 20 lM SB202190; GO
out () or with TNF-a (+, 10 ng/ml). Secreted adiponectin was detecte
r 6 h, 3T3-L1 adipocytes were pretreated with diﬀerent concentration
gures show representative results of three independent experiments an
. **P < 0.01, *P < 0.05, compared with TNF-a alone-treated cells.1
,
d
s
d
Fig. 2. Eﬀect of GO6976 on TNF-a-induced downregulation of adiponectin expression. (A) Fully diﬀerentiated 3T3-L1 adipocytes were treated as in
Fig. 1A and total RNA and whole cell lysates were prepared and analyzed by semi-quantitative RT-PCR and immunoblotting, respectively. GAPDH
and actin were used as internal loading controls. (B–C) The dose-dependent eﬀect of GO6976 on adiponectin mRNA and protein expression was
examined by semi-quantitative RT-PCR (B) and immunoblotting (C), respectively. Induction of PAI-1 mRNA via TNF-a-induced PKC activation
was included to conﬁrm the eﬀect of GO6976.
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internal control), 5 0-ACCACAGTCCATGCCATCAC-3 0 (forward)
and 5 0-TCCACCACCCTGTTGCTGTA-3 0 (reverse). PCR products
were separated by electrophoresis through 1% agarose at 100 V for
20 min, and ethidium bromide stained bands were detected using a
UV transilluminator.
2.5. Protein isolation and immunoblotting
Protein isolation and immunoblotting were performed as described
previously [17]. Brieﬂy, cells were lysed with RIPA buﬀer (50 mM
Tris–HCl, pH 7.4, 150 mM NaCl, 1% NP-40, 0.25% Na-deoxycholate,
1 mM EDTA, 2 mM EGTA) containing a protease inhibitor cocktail
of 1 mM Na3VO4, 1 mM NaF, and 1 mM PMSF (Sigma). Thirty lg
aliquots of whole cell extract were separated by SDS–PAGE and trans-
ferred to nitrocellulose membranes by electroblotting for 2 h at 100 V.
For detection of secreted adiponectin, 40 ll of culture medium was
used for electrophoresis. Membranes were blocked with 5% non-fat
dry milk dissolved in Tris-buﬀered saline (10 mM Tris–Cl, pH 8.0,
150 mMNaCl, 0.1% Tween-20) for 1 h at room temperature. The blots
were probed with primary antibody for 2 h at room temperature or
overnight at 4 C, and then incubated with horseradish peroxidase
(HRP)-conjugated secondary antibodies (Santa Cruz Biotechnology)
for 1 h at room temperature. Immunoreactive bands were detected
using an enhanced chemiluminescence detection kit (Amersham
Biosciences).
2.6. Statistical analysis
All values are reported as means ± standard deviation (S.D.). Statis-
tical comparison between experimental groups was performed using
Students t-test. P-values < 0.05 were considered statistically signiﬁcant.3. Results
3.1. TNF-a-induced suppression of adiponectin expression and
secretion is attenuated by PKC inhibitor GO6976
Fully diﬀerentiated 3T3-L1 adipocytes exhibited oil red-po-
sitive staining (data not shown) and abundantly secreted a
30-kD protein corresponding to adiponectin. Treatment with
TNF-a for 24 h dramatically suppressed the secretion ofadiponectin (Fig. 1A). Pretreatment with GO6976, a selective
inhibitor of conventional PKC isoforms, alleviated the TNF-
a-induced suppression of adiponectin secretion with a greater
eﬀect than JNK inhibitor (SP600125), p38MAPK inhibitor
(SB202190), or ERK inhibitor (U0126). Furthermore, the
inhibitory action of GO6976 was dose-dependent; little eﬀect
was observed at concentrations <1 lM, but adiponectin secre-
tion was restored to 76% of untreated controls with 2 lM
GO6976 (Fig. 1B). Treatment with inhibitors alone did not al-
ter adiponectin secretion levels (data not shown).
To investigate whether the eﬀect of GO6976 on adiponectin
secretion is due to its expressional regulation, we examined
adiponectin mRNA and protein levels depending on various
treatments. In parallel with the secretion pattern of adiponec-
tin, GO6976 restored the TNF-a-induced suppression of
adiponectin expression at both mRNA and protein levels
(Fig. 2A). Similar to GO6976, SP600125 also showed the same
eﬀect, suggesting an involvement of JNK signaling as previ-
ously reported [13]. Additionally, we observed dose-dependent
eﬀect of GO6976 on both adiponectin mRNA and protein
expression, showing maximum eﬀect at 2 lM (Fig. 2B and
C). This result suggests that the eﬀect of GO6976 on adiponec-
tin secretion result from the expressional regulation of adipo-
nectin. Diﬀerent from adiponectin, plasminogen activator
inhibitor-1 (PAI)-1 is induced by TNF-a via PKC signaling
[14]. GO6976 suppressed TNF-a-induced PAI-1 expression at
mRNA level (Fig. 2B), suggesting that 3T3-L1 adipocytes used
in this experiment normally response to PKC inhibitor
GO6976.
3.2. PKC is involved in TNF-a-induced JNK activation
Activation of JNK 1/2 plays an important role in TNF-a-in-
duced downregulation of adiponectin in 3T3-L1 adipocytes
[13]. To investigate whether PKC functions upstream of
JNK, we examined the eﬀect of GO6976 on TNF-a-induced
Fig. 3. TNF-a-induced activation of JNK signaling was blocked by GO6976. Fully diﬀerentiated 3T3-L1 adipocytes were serum starved for 6 h and
then pretreated with 2 lM GO6976 for 1 h prior to incubation without () or with TNF-a (+, 10 ng/ml) for 24 h. (A) Thirty microliter aliquots of
whole cell lysate were used for detecting phospho-MAPKs by immunoblotting with anti-phospho-JNK1/2, anti-phospho-ERK1/2, and anti-
phospho-p38MAPK antibodies. Antibodies against total JNK1/2, ERK1/2, and p38MAPK were used as internal loading controls. The ﬁgures show
representative results of three independent experiments (left) and the graph represents mean value of quantiﬁcations by densitometric analysis (right).
(B) Phosphorylated c-Jun and ATF2 were detected using anti-phospho-c-Jun (left) and anti-phospho-ATF2 antibodies (right). Actin and total ATF2
were used as internal controls. (C) After serum starvation for 6 h, 3T3-L1 adipocytes were pretreated with various concentrations of GO6976 (0.01–
2 lM) for 1 h prior to treatment without () or with TNF-a (+, 10 ng/ml) for 24 h. Phospho-ATF2 was detected by immunoblotting using anti-
phospho-ATF2 antibodies. Total ATF2 was detected by loading in a separate membrane as an internal loading control. The ﬁgures show
representative results of three independent experiments and the graph represents mean value of quantiﬁcations by densitometric analysis.
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substantial increase in JNK1/2 phosphorylation, which was
blocked by pretreatment with GO6976 (Fig. 3A and B).
TNF-a also increased the phosphorylation of other MAPKs
including ERK1/2 and p38MAPK, but these activations were
rarely altered by GO6976. To further investigate whether pre-
treatment with GO6976 could aﬀect the activation of JNK
downstream signaling, we examined phosphorylation of c-
Jun and ATF2. TNF-a enhanced the phosphorylation of c-
Jun and ATF2, which was attenuated by pretreatment with
GO6976 (Fig. 3C and D). These results suggest that PKC
could play a role as an upstream signaling mediator in TNF-
a-induced JNK activation.
3.3. PKC inhibits the transcriptional activity of PPARc on
adiponectin promoter
It is well known that PPARc plays a pivotal role in the induc-
tion of adiponectin as a transcription factor and that TNF-a sup-presses the expression of adipogenic genes by inhibiting the
transcriptional activity of adipogenic transcription factors
including PPARc. In this regard, we examined whether PKC
could mediate TNF-a-induced downregulation of adiponectin
expression through regulation of transcriptional activity of
PPARc.Weobserved that TNF-a suppressed the transcriptional
activity of PPARc on adiponectin promoter (1.5 kb) in
PPARc-overexpressed cells, which was signiﬁcantly restored by
pretreatment with GO6976 (Fig. 4A). Furthermore, PPARc-
dependent transcriptional activation was inhibited in a PKC iso-
form-dependentmanner.OverexpressionofPKCaorPKCb, but
not PKCd or PKCe, commonly suppressed PPARc-dependent
activation of adiponectin promoter (Fig. 4B) and PPRE
(PPARc-responsive element) reporter (Fig. 4C).
Taken together, these results raise the possibility that PKC
might be involved in TNF-a-induced downregulation of adipo-
nectin, at least in part, through inhibition of transcriptional
activity of PPARc.
Fig. 4. Eﬀects of PKCs on transcriptional activity of PPARc. (A) Fully diﬀerentiated 3T3-L1 adipocytes were co-transfected with adiponectin
promoter-luc (0.5 lg/well) and PPARc (0.4 lg/well) with b-galactosidase (100 ng/well). After 24 h incubation, cells were pretreated with GO6976
(2 lM) for 1 h prior to treatment without () or with TNF-a (+, 10 ng/ml) for additional 24 h. Luciferase activity was measured and normalized to b-
galactosidase activity. HEK293 cells were co-transfected with b-galactosidase (100 ng/well) and adiponectin promoter-luc (B) or PPRE-luc (C)
(0.5 lg/well), together with PPARc (0.5 lg/well) and each PKC isoform expression vector (0.3 lg/well). The total amount of DNA transfected was
kept constant using pcDNA3.1 empty vector. Results shown are the mean value of three independent experiments. **P < 0.01, *P < 0.05, compared
with PPARc alone-transfected cells.
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The expression and secretion of adiponectin is regulated by a
variety of hormones and cytokines that inﬂuence insulin sensi-
tivity in adipocytes. TNF-a, a cytokine that induces insulin
resistance, functions as a major negative regulator of adiponec-
tin and causes metabolic disorders by impairing the function of
adipose tissues [18]. Due to the protective eﬀect of adiponectin
against insulin-associated metabolic diseases, TNF-a-induced
reduction of adiponectin expression is considered a crucial
event in the development of insulin resistance. Therefore, a
precise understanding of the relationship between these adipo-
kines and their regulatory mechanisms will be valuable in the
development of treatments for insulin-related metabolic syn-
dromes and alcohol-related liver injury.
In this study, we investigated the involvement of PKC in
TNF-a-induced suppression of adiponectin expression in fully
diﬀerentiated 3T3-L1 adipocytes, using GO6976 as a selective
inhibitor of PKC. Pretreatment with GO6976 attenuated the
suppressions of adiponectin secretion and expression induced
by TNF-a. GO6976 is generally used as a PKC inhibitor; how-
ever, it is also known to inhibit other protein kinases including
S6K1, MAPKAP-K1RSK2, MSK1, CHK1 and PHK [19].
Although we did not check the activities of these kinases and
thus we can not completely exclude the association with them
in the action of GO6976 at present, our data suggest that PKC
is closely implicated in the adiponectin regulation in cultured
adipocytes. Indeed, another PKC inhibitor, GO6983 also
showed the similar eﬀect (data not shown).We observed that treatment with TNF-a rapidly activated
JNK in cultured 3T3-L1 adipocytes, which is consistent with
the previous report demonstrating the involvement of JNK
in suppression of adiponectin expression [13]. Furthermore,
it is known that the activation of c-Jun and ATF2 following
JNK activation regulates PPARc expression via Map4k4 stim-
ulation, thereby contributing to suppression of adipogenesis
[20]. Here, we showed that GO6976 suppressed TNF-a-in-
duced activations of c-Jun and ATF2 as well as JNK, suggest-
ing that PKC may play a role as an upstream signaling
mediator of TNF-a-induced JNK activation for regulation of
adiponectin expression.
PKCs play diverse roles in physiological functions including
insulin signal transduction and diﬀerentiation of adipocytes;
however, the precise role of the respective isoforms in adipocytes
remains to be elucidated. Activation of atypical PKC isoforms
(aPKC)/protein kinase B (PKB/AKT) is responsible for insu-
lin-stimulated glucose transport through insulin receptor sub-
strate-1 (IRS-1)-dependent PI3K signaling pathway, which is
defective in type-2 diabetic and obese animal and human sub-
jects [21]. TNF-a contributes to insulin resistance by inhibiting
insulin-dependent activation of the IRS-PI3K-PKCb/f signaling
cascade [22]. Meanwhile, PKC-d accounts for production of
reactive oxygen species (ROS) inducing oxidative stress in
high-fat diet-induced obese and insulin resistance mice [23].
Thus, the functional role of PKCs may vary depending on iso-
form and environmental conditions. In line with this, we ob-
served PKCs diﬀerentially inhibit transcriptional activity of
PPARc in PKC isoform-speciﬁc manner. Transient expression
3478 J.-Y. Lim et al. / FEBS Letters 582 (2008) 3473–3478of PKCa or PKCb attenuated PPARc-induced activations of
adiponectin promoter and PPRE reporter, meanwhile PKCd
and PKCe did not show such inhibitory eﬀect. Considering that
PKCa plays an important role in exerting the anti-adipogenic ef-
fect of PDGF in 3T3-L1 adipocytes [24], it is possible that PKCa
is involved in TNF-a-induced suppression of adiponectin.
Taken together, our results suggest that PKC could be in-
volved in TNF-a-induced downregulation of adiponectin
expression and secretion through regulation of transcriptional
activity of PPARc in cultured 3T3-L1 adipocytes. These ﬁndings
provide a new basis for the development of therapeutic agents
for treating metabolic disorders such as diabetes and obesity.
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